Sagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming Neutraceutical

BAYTOWN, TX / ACCESSWIRE / May 1, 2024 / Sagaliam Acquisition Corp ("SAGA", the "Company") (NASDAQ:SAGA) announced today that Virogentics, Inc., a wholly owned subsidiary of SAGA ("VIRO"), and the Bulgarian product development team, headed by Dr. Lachezar Ivanov and Harry Zhabilov, CSO, have developed a new IPF formula which combines a Vitamin C component with the existing patented compound. This product will be marketed as IPF Immune+ with Vit C. In addition, this new product will be available in both pill and lozenge form providing convenience and a more effective delivery for the users. The team has also begun production of a new slimming formula which will be added to the VIRO nutraceutical product line.

Barry Kostiner, the CEO of Sagaliam, commented, "Our IPF nutraceutical has received strong consumer approval, and we look forward to ramping up our marketing efforts, in parallel with our other nutraceutical products. We are grateful for our relationship with Enzolytics and look forward to participating in its development of Sales, Marketing and Distribution infrastructure to service our expanded portfolio of consumer wellness products. Sagaliam's partnership with Dr. Lachezar Ivanov has resulted in a pipeline of significant consumer nutraceutical products. In addition to IPF Immune, we will be working with Dr. Ivanov to deliver brain detox and liver detox nutraceuticals to the American market, as well as our latest development, IPF immune formulated in tablets and lozenges with Vitamin C."

About Sagaliam Acquisition Corp.

We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. Sagaliam intends to continue to pursue the consummation of a business combination with an appropriate target.

Virogentics, a subsidiary of Sagaliam, is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.